134,710 Shares in Fulgent Genetics, Inc. $FLGT Acquired by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC purchased a new stake in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 134,710 shares of the company’s stock, valued at approximately $2,678,000. Brandywine Global Investment Management LLC owned approximately 0.44% of Fulgent Genetics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Signaturefd LLC grew its holdings in shares of Fulgent Genetics by 60.4% during the second quarter. Signaturefd LLC now owns 1,914 shares of the company’s stock valued at $38,000 after buying an additional 721 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Fulgent Genetics by 122.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,562 shares of the company’s stock worth $60,000 after acquiring an additional 1,963 shares during the period. State of Wyoming lifted its position in Fulgent Genetics by 111.1% during the 1st quarter. State of Wyoming now owns 6,564 shares of the company’s stock worth $111,000 after acquiring an additional 3,455 shares during the period. Headlands Technologies LLC grew its stake in Fulgent Genetics by 8.0% during the 1st quarter. Headlands Technologies LLC now owns 7,041 shares of the company’s stock valued at $119,000 after purchasing an additional 524 shares during the last quarter. Finally, Aigen Investment Management LP increased its holdings in shares of Fulgent Genetics by 11.3% in the first quarter. Aigen Investment Management LP now owns 13,081 shares of the company’s stock valued at $221,000 after purchasing an additional 1,328 shares during the period. Hedge funds and other institutional investors own 48.06% of the company’s stock.

Insider Buying and Selling

In other Fulgent Genetics news, COO Jian Xie sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $29.10, for a total transaction of $291,000.00. Following the completion of the transaction, the chief operating officer directly owned 349,768 shares in the company, valued at approximately $10,178,248.80. This represents a 2.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have sold 14,333 shares of company stock valued at $385,278. 31.76% of the stock is currently owned by insiders.

Fulgent Genetics Trading Up 2.2%

NASDAQ FLGT opened at $30.65 on Tuesday. The stock has a market capitalization of $947.45 million, a price-to-earnings ratio of -18.46 and a beta of 0.92. The stock has a 50-day moving average of $24.22 and a 200 day moving average of $21.72. Fulgent Genetics, Inc. has a twelve month low of $14.57 and a twelve month high of $30.67.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Friday, November 7th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.36. Fulgent Genetics had a negative return on equity of 2.26% and a negative net margin of 16.83%.The business had revenue of $84.07 million during the quarter, compared to analysts’ expectations of $81.43 million. Fulgent Genetics has set its FY 2025 guidance at 0.300-0.300 EPS. Equities analysts predict that Fulgent Genetics, Inc. will post -0.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on FLGT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulgent Genetics in a research report on Wednesday, October 8th. Piper Sandler upped their price objective on shares of Fulgent Genetics from $21.00 to $30.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Wall Street Zen upgraded shares of Fulgent Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. UBS Group upgraded shares of Fulgent Genetics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $20.00 to $30.00 in a research report on Tuesday, August 5th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Fulgent Genetics in a report on Friday, November 14th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $32.00.

Fulgent Genetics Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.